HC Wainwright & Co. Reiterates Akebia Therapeutics (AKBA) Neutral Recommendation
27/5 01:22
Fintel reports that on May 26, 2023, HC Wainwright & Co. reiterated coverage of Akebia Therapeutics (NASDAQ:AKBA) with a Neutral recommendation....
|
|
|
27/5 01:22
Fintel reports that on May 26, 2023, HC Wainwright & Co. reiterated coverage of Akebia Therapeutics (NASDAQ:AKBA) with a Neutral recommendation....